source
- Sensorion, citing Regeneron competition, shifts focus to a different hearing loss therapyA strategic review determined that the development environment had "notably changed," leading Sensorion to end work on its gene therapy for OTOF-related hearing loss.BioPharma Dive · 1mo ago↗ source
- Summit withdraws $500M offering, citing 'market conditions'The current biotech environment can apparently support an industry-record IPO and simultaneously hamper efforts to raise half a billion dollars. Summit Therapeutics ditched plans for a $500 million…Endpoints · 1mo ago↗ source
- STAT+: A suspicious denial pattern in Medicare AdvantageMajor Medicare Advantage plans almost always reversed their denials on appeal, raising big questions about barriers to care.STAT · 1mo ago